Remember Lazard, QCOR TP at $74 last year when most weenie analysts were trashing the company. Here is what they said in mid-August, which I believe is right on the money. Thought it was worth a re-post. Their target price is currently $85.
"New opportunity: ex-US Acthar for Infantile Spasm...Synacthen franchise will enable global capabilities."
Note: I couldn't agree more. Huge unmet need, likely will lead to 10-year orphan indication. IS population in the EU is 2x the US. 18-24 months to commercialization in my opinion, using current randomized data. Annual revenue estimate beginning 2016: $100-$150 million.
But in the immediate, simply a mention of this opportunity in the Q3 conference call should be met with a lot of enthusiasm from investors.
I was quite surprized to realize some years ago that politicians and probably IR depts love to hear from their constituants. I found if I called personally and addressed my issuses, I actually got a positive response. I think you have done the same Pman. Potholes, traffic lights, graffiti were all taken care of and I hope you had a chance to "oach" Patty on some of the subjects we investors are hoping to hear on the CC. Good on ya bro...
No worries Saram--MaxD handled that part of the dialog.
He gave Patty at least four detailed communication assignments and requested prompt action.
All were very good suggestions--including a grid of current trial activity, a formula for bashers, and more regular communications.